Opendata, web and dolomites

ThyroTrust

A novel reliable diagnostic device to avoid unnecessary thyroid surgery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ThyroTrust project word cloud

Explore the words cloud of the ThyroTrust project. It provides you a very rough idea of what is the project "ThyroTrust" about.

performed    types    ce    forcing    cytological    rearrangements    fnac    ipr    histology    diagnostic    clinically    postoperative    proposing    26    manufacturing    life    virtually    surgery    quality    prevalence    route    risk    47    reveal    benign    kit    thyrotrust    addressable    first    financial    category    outcome    million    organization    diagnostics    15    business    cos    strategy    30    thyroid    validated    price    time       estimation    generation    740    introduce    replacement    idea    lesion    expression    frequent    measured    fna    hormone    either    planning    90    gene    effect    thyroidectomy    market    abolishment    tool    malignancy    genes    positive    surgeries    lt    complications    opportunity    correct    innovation    66    plan    social    patients    surgical    italy    negative    ing    ivd    malignant    adverse    feasibility    44000    nodules    sequencing    classified    variations    panel    cytology    fine    80    aspiration    prudentially    influences    cancer    considerable    300    procedure    search    clinical    needle    scope    unnecessary    diagnosis    indeterminate   

Project "ThyroTrust" data sheet

The following table provides information about the project.

Coordinator
GENOMNIA SRL 

Organization address
address: CORSO MAGENTA 56
city: MILANO
postcode: 20123
website: www.genomnia.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.genomnia.it
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOMNIA SRL IT (MILANO) coordinator 50˙000.00

Map

 Project objective

Fine needle aspiration cytology (FNAC) is the best procedure for a timely and reliable diagnosis of either a benign or malignant thyroid lesion. However, the management of patients with indeterminate cytology (10-26%) is a frequent clinical and social problem, as this cytological category is associated with a 15 to 30% prevalence of malignancy, forcing most of these patients to diagnostic surgery. However, for the 80% of these patients the surgery is unnecessary as the postoperative histology reveal a benign lesion. The negative social and financial consequences of this approach are relevant in Europe (44000/year thyroidectomy only in Italy) as well as the adverse influences on the quality of life of the patients due to surgical complications and hormone replacement. We will introduce in the market the first clinically validated CE-IVD targeted Next Generation Sequencing diagnostic kit ThyroTrust for the correct diagnosis of thyroid nodules with indeterminate cytology. Our kit is the first to include a considerable number of variations in 47 genes, 66 types of rearrangements and 8 gene expression level measured at the same time and associated with malignant outcome. This will avoid diagnostic surgery if a risk of malignancy <5%. In the scope of the feasibility study we will assess: - Technology innovation opportunity and business idea - Development planning and partner search - IPR, quality, organization and manufacturing route - GO-TO-MARKET strategy and business plan 740,000 FNA are performed in Europe, so the addressable market, with an end-user price/kit of 300€, is over €50 Million/year. Prudentially, market estimation considers only FNA results classified as “indeterminate cytology”. The same approach could be evaluated and adopted for other cancer diagnostics, proposing a similar gene panel kit on the market. The positive effect resulting from such diagnostic tool can virtually lead to the abolishment of 90% of unnecessary surgeries and related cos

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THYROTRUST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THYROTRUST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More